Palmoplantar Pustulosis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Palmoplantar Pustulosis Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Palmoplantar Pustulosis epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Palmoplantar Pustulosis therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Palmoplantar Pustulosis Market with DelveInsight's In-Depth Report @ Palmoplantar Pustulosis Market Size- https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Palmoplantar Pustulosis Market Report
• In June 2025, Boehringer Ingelheim announced a study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027). The goal of this study is to find out how well people with GPP tolerate long-term treatment with spesolimab. The study also tests whether spesolimab helps improve GPP symptoms and how quickly the symptoms improve after a flare-up.
• In June 2025, Takeda conducted a study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.
• In the EU4 & the UK, Germany accounted for the highest Palmoplantar Pustulosis Drugs Market share in 2023, with around 60% followed by France and the UK; these numbers are expected to increase during the forecast period (2024-2034).
• Palmoplantar Pustulosis can affect individuals of all ages, with females being more likely to be affected than males.
• In 2023, Japan accounted for the highest number of Palmoplantar Pustulosis diagnosed prevalent cases.
• In the United States, individuals of the 40-64 year age group reported the highest number of Palmoplantar Pustulosis cases.
• In EU4 and the UK, Germany accounted for the highest number of Palmoplantar Pustulosis diagnosed prevalent cases in 2023, while Spain accounted for the lowest number of diagnosed prevalent cases.
• In 7MM, Mild cases outnumbered moderate-severe cases in 2023.
• The leading Palmoplantar Pustulosis Companies such as Kyowa Kirin Co. Ltd, Amgen, Janssen Pharmaceuticals, AbbVie, Aristea Therapeutics Inc., AnaptysBio Inc., Boehringer Ingelheim, CSL Behring, Novartis Pharmaceuticals, Innovaderm Research Inc., Shanghai Huaota Biopharmaceutical Co. Ltd., Eli Lilly and Company, and others.
• Promising Palmoplantar Pustulosis Pipeline Therapies such as Apremilast, KHK4827, Guselkumab, RIST4721, Imsidolimab, Risankizumab, Spesolimab and others.

Stay ahead in the Palmoplantar Pustulosis Therapeutics Market with DelveInsight's Strategic Report @ Palmoplantar Pustulosis Market Outlook- https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Palmoplantar Pustulosis Epidemiology Segmentation in the 7MM
• Total Palmoplantar Pustulosis Diagnosed prevalent cases
• Palmoplantar Pustulosis Age-specific cases
• Palmoplantar Pustulosis Gender-specific cases
• Palmoplantar Pustulosis Severity-specific cases
• Total Palmoplantar Pustulosis Treated cases

Download the report to understand which factors are driving Palmoplantar Pustulosis epidemiology trends @ Palmoplantar Pustulosis Prevalence- https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Palmoplantar Pustulosis Marketed Therapies
• LUMICEF (brodalumab): Kyowa Kirin
Kyowa Kirin received approval from the Ministry of Health, Labour, and Welfare (MHLW) in Japan in August 2023, for a partial change in the approved indication of LUMICEF (brodalumab) to include the Palmoplantar Pustulosis treatment in patients who have had an inadequate response to existing therapies. LUMICEF is a fully human anti-interleukin-17 (IL-17) receptor. An antibody that selectively inhibits inflammatory cytokines like IL-17A, IL-17A/F, IL-17F, and IL-17C by binding to the IL-17A receptor. This makes it the first IL-17 pathway inhibitor approved for PPP. The approval is based on positive results from a Phase III clinical trial in Japan, which showed that LUMICEF met its primary endpoint, confirming its efficacy and safety for PPP patients.

• SKYRIZI (risankizumab): AbbVie/ Boehringer Ingelheim
SKYRIZI (risankizumab) is a monoclonal antibody that works by binding to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the inflammatory process. By binding to this subunit, risankizumab effectively prevents IL-23 from interacting with its receptor on immune cells. This Palmoplantar Pustulosis mechanism of action helps to reduce the inflammatory responses that are associated with certain autoimmune conditions, including PPP. By inhibiting the IL-23/IL-23 receptor interaction, risankizumab can modulate the immune system and reduce the overactive immune response that drives the Palmoplantar Pustulosis symptoms. Currently, risankizumab is approved in Japan for the Palmoplantar Pustulosis treatment, providing a targeted therapeutic option for patients with this chronic and challenging condition

Palmoplantar Pustulosis Emerging Therapies

• OTEZLA (apremilast): Amgen
OTEZLA (apremilast market) is an oral medication used to treat certain types of psoriasis and psoriatic arthritis. It works as a selective inhibitor of phosphodiesterase 4 (PDE4), which helps to reduce inflammation. In the United States, OTEZLA is approved for the treatment of adults with active psoriatic arthritis, plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, and oral ulcers associated with Behçet's disease. In the European Union, OTEZLA is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response to or have been intolerant of prior disease-modifying antirheumatic drug (DMARD) therapy. It is also approved for moderate to severe chronic plaque psoriasis in adults who have not responded to, are contraindicated for, or are intolerant of other systemic therapies such as cyclosporine, methotrexate, or psoralen and ultraviolet-A light.

Get In-Depth Knowledge on Palmoplantar Pustulosis Market Trends and Forecasts with DelveInsight @ Palmoplantar Pustulosis Treatment Market- https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Palmoplantar Pustulosis Market Outlook
While no medications are currently FDA-approved specifically for PPP, several therapeutic options show promise. Topical treatments can be effective for patients with limited disease, though long-term responses are often not sustained. Systemic therapies, including biologics, JAK inhibitors, DMARDs, and retinoids, may achieve PPP clearance, but come with potential side effects. Phototherapy is also effective, though it can present challenges related to accessibility and cost.

Palmoplantar Pustulosis Therapeutics Market
Palmoplantar Pustulosis is a chronic skin condition characterized by the appearance of yellow-brown pustules on the palms of the hands and the soles of the feet. Once considered a type of psoriasis, Palmoplantar Pustulosis is now classified separately, though 10-25% of individuals with Palmoplantar Pustulosis may also have chronic plaque psoriasis.

Unlock Strategic Insights with DelveInsight's Comprehensive Palmoplantar Pustulosis Market Report @ Palmoplantar Pustulosis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Palmoplantar Pustulosis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Palmoplantar Pustulosis Companies- Kyowa Kirin Co. Ltd, Amgen, Janssen Pharmaceuticals, AbbVie, Aristea Therapeutics Inc., AnaptysBio Inc., Boehringer Ingelheim, CSL Behring, Novartis Pharmaceuticals, Innovaderm Research Inc., Shanghai Huaota Biopharmaceutical Co. Ltd., Eli Lilly and Company, and others.
• Palmoplantar Pustulosis Pipeline Therapies- Apremilast, KHK4827, Guselkumab, RIST4721, Imsidolimab, Risankizumab, Spesolimab and others.
• Palmoplantar Pustulosis Therapeutic Assessment: Palmoplantar Pustulosis current marketed and Preeclampsia emerging therapies
• Palmoplantar Pustulosis Market Dynamics: Palmoplantar Pustulosis market drivers and Palmoplantar Pustulosis market barriers
• Palmoplantar Pustulosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Palmoplantar Pustulosis Unmet Needs, KOL's views, Analyst's views, Palmoplantar Pustulosis Market Access and Reimbursement

Get More Insights of the Market Research Report @ https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. PPP Market Overview at a Glance
4. Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Treatment and Management of PPP
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Palmoplantar Pustulosis (PPP): 7 Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.